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Abstract
The risk factors for complications in patients with influenza A (H1N1)v virus infection have not been fully elucidated. We performed an
observational analysis of a prospective cohort of hospitalized adults with confirmed pandemic influenza A (H1N1)v virus infection at 13
hospitals in Spain, between June 12 and November 10, 2009, to identify factors associated with severe disease. Severe disease was
defined as the composite outcome of intensive-care unit (ICU) admission or in-hospital mortality. During the study period, 585 adult
patients (median age 40 years) required hospitalization because of pandemic (H1N1) 2009. At least one comorbid condition was pres-
ent in 318 (54.4%) patients. Pneumonia was diagnosed in 234 (43.2%) patients and bacterial co-infection in 45 (7.6%). Severe disease
occurred in 75 (12.8%) patients, of whom 71 required ICU admission and 13 (2.2%) died. Independent factors for severe disease were
age <50 years (OR, 2.39; 95% CI, 1.05–5.47), chronic comorbid conditions (OR, 2.93; 95% CI, 1.41–6.09), morbid obesity (OR,
6.7; 95% CI, 2.25–20.19), concomitant and secondary bacterial co-infection (OR, 2.78; 95% CI, 1.11–7) and early oseltamivir therapy
(OR, 0.32; 95% CI 0.16–0.63). In conclusion, although adults hospitalized for pandemic (H1N1) 2009 suffer from significant morbidity,
mortality is lower than that reported in the earliest studies. Younger age, chronic comorbid conditions, morbid obesity and
bacterial co-infection are independent risk factors for severe disease, whereas early oseltamivir therapy is a protective factor.
Keywords: Epidemiology, influenza A (H1N1) 2009, intensive-care unit, mortality, risk factors
Original Submission: 1 July 2010; Revised Submission: 23 July 2010; Accepted: 19 August 2010
Editor: D. Raoult
Article published online: 3 September 2010
Clin Microbiol Infect 2011; 17: 738–746
10.1111/j.1469-0691.2010.03362.x
Corresponding author: J. Carratala`, Department of Infectious
Diseases, Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907,
L’Hospitalet de Llobregat, Barcelona, Spain
E-mail: jcarratala@ub.edu
*Other members of the Novel Influenza A(H1N1) Study Group are:
J. Niubo1, A. Martı´n-Quiro´s2, M. Romero-Go´mez2, G. Ruı´z-
Carrascoso2, J. C. Figueira2, M. C. Prados2, E. Cordero3, E. Garcı´a-
Cabrera3, M. Riera4, J. M. Aguado5, J. Vila5, A. Payeras6, M. Garcı´a-
Gasalla6, J. L. Gonza´lez-Ferna´ndez7, M. Gutie´rrez-Cuadra7, M. V.
Sanjuan7, J. A. Parra7, L. Linares8, I. Hoyo8, M. A´. Marcos8, T. Puma-
rola8, M. de Cueto9, M. A. Muniain9, M. D. del Toro9, L. Pe´rez-Martı´-
nez10, J. R. Blanco10, M. Sanz10, L. Metola10, V. Ibarra10, L. Ortega11,
R. Lara12, M. Causse12, E. M. Gonza´lez13.
Introduction
Influenza pandemics have been associated with increased
morbidity and mortality. Each pandemic is different and there
are always a series of unknowns when an influenza virus
emerges and becomes pandemic [1,2]. In April 2009, a novel
influenza virus, now known as influenza A (H1N1)v virus,
caused an outbreak of respiratory disease in Mexico [3] and
spread rapidly throughout the world. Spain was the first
country in Europe to report a laboratory-confirmed case of
new influenza A (H1N1)v virus infection [4]. The number of
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hospitalizations and deaths caused by pandemic (H1N1) 2009
increased continuously until December 2009.
The studies published indicate that there are differences
between pandemic (H1N1) 2009 and seasonal influenza.
Among adult patients, pandemic (H1N1) 2009 affects mainly
those under the age of 60 years with chronic underlying dis-
eases, pregnant women, and obese patients [5–7]. The over-
all mortality of this infection is similar to that presented by
seasonal influenza and lower than previous pandemics [8–
10], although mortality varies considerably between coun-
tries [8]. There is also concern that subsequent waves of
influenza pandemic could be more lethal than the first [2].
Little information is currently available on factors associ-
ated with severe disease in adults hospitalized for the pan-
demic influenza (H1N1)v virus. Moreover, the few studies
published to date have been limited by small sample size
[5,11–13], retrospective design [13,14], analysis based merely
on database surveillance reports [15,16], or inclusion of only
critically ill patients [11,17]. To identify risk factors for
severe disease, and hence to determine the optimal case
management and prevention, more clinical and treatment
data of the pandemic (H1N1) 2009 are needed.
The aim of the present multicentre study was to ascertain
factors associated with severe disease among adults hospital-
ized for pandemic (H1N1) 2009 in Spain.
Materials and Methods
Setting, patients and study design
This prospective cohort study was conducted at 13 tertiary
hospitals belonging to the Spanish Network for Research in
Infectious Diseases (REIPI). All adult patients admitted to the
hospital for at least 24 h with confirmed influenza A (H1N1)
virus infection from June 12 to November 10, 2009, were
prospectively recruited and followed up. Following the
recommendations of the Spanish Ministry of Health, specific
laboratory tests for influenza A (H1N1)v virus (see below)
were performed on all patients with community-onset pneu-
monia or influenza-like symptoms in any of the following
circumstances: pregnancy, underlying chronic conditions,
morbid obesity, and in the presence of complications [18]. If
the first test was negative, a new sample was recommended
whenever the clinical syndrome had not clearly improved.
The results were typically available in <24 h (frequently
<12 h).
Cases were detected on a daily basis by reviewing the
microbiological reports. A confirmed case was defined as a
person with an influenza-like illness with laboratory-
confirmed pandemic influenza A (H1N1) virus infection using
real-time polymerase chain reaction or viral culture [19].
Pandemic influenza A (H1N1)v virus testing was performed
at each institution. For the purposes of this study patients
were divided into two groups: severe disease and no severe
disease. Severe disease was defined as the composite out-
come of intensive-care unit (ICU) admission or in-hospital
mortality. The study was approved by the Ethics Committee
of the coordinating centre, the Hospital Universitari de Bell-
vitge, and informed consent was obtained from patients.
Clinical assessment and follow-up
Microbiological studies, hospital and ICU admission criteria,
and treatment decisions were not standardized and were
made by attending physicians at each study centre. Patients
were seen during their hospital stay by one or more of the
investigators at each participating hospital, who recorded
clinical data in a standardized, computer-assisted protocol.
Data were collected on demographic characteristics, comor-
bid conditions, body mass index (BMI, the weight in kilo-
grams divided by the square of the height in metres), clinical
signs and symptoms, biochemical analysis, chest radiograph
findings, antiviral and antibacterial therapy, concomitant and
secondary bacterial co-infection, and outcomes, including
mortality. A long-term follow-up visit was scheduled
1 month after discharge. For time calculations, the day of
admission was considered to be hospital day 0, except for
time to antiviral administration in which the day of symptoms
onset was considered day 0. Completed protocols were sent
to the coordinating centre and all data were carefully
reviewed by two clinical investigators (DV and JC) before
the final validation.
Definitions
Comorbidities were assessed using the Charlson Comorbidi-
ty Index definitions [20]. Other comorbidities, such as immu-
nosuppression, neuromuscular disorders and sickle-cell
disease, were also recorded. Obesity was defined as a BMI
‡30–39.9 and morbid obesity as a BMI ‡ 40 or a subjective
assessment by the physician if weight and height were not
available. Tobacco abuse was recorded when a patient had
smoked more than ten cigarettes per day for at least 1 year
preceding the study. Alcohol abuse was considered if alcohol
intake was more than three standard drinks per day. Vacci-
nation status was assessed from interviews with the patients
or their relatives and from reviews of hospital and personal
health records (vaccination card). Patients were considered
to be pneumococcus-vaccinated if 23-valent polysaccharide
pneumococcal vaccine had been administered in the 5 years
before admission, and influenza-vaccinated if seasonal influ-
enza vaccine had been administered during the year before
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admission. Pneumonia was defined as the presence of a new
infiltrate on a chest radiograph plus fever (temperature
‡38.0C) and respiratory symptoms. Concomitant and sec-
ondary bacterial co-infection were diagnosed in patients with
one or more positive cultures obtained from blood, normally
sterile fluids, or sputum and a positive Streptococcus pneumo-
niae urinary antigen. Complications were defined as any
untoward circumstances occurring during hospitalization.
Mortality was defined as death from any cause during
hospitalization.
Statistical analysis
The results were analysed using a commercially available sta-
tistical software package (SPSS, version 15.0; SPSS Inc, Chi-
cago, IL, USA). Descriptive statistics were performed for all
study variables. All proportions were calculated as percent-
ages of the patients with available data. To detect significant
differences between groups, we used the chi-square test or
Fisher exact test for categorical variables and the t-test or
Mann–Whitney U-test for continuous variables, when appro-
priate. The multivariate logistic regression analysis of factors
potentially associated with severe disease included the
variables that were significant in the univariate analysis and
clinically important variables, whether they were significant
or not. The relative risks were expressed as OR and 95%
CI. Statistical significance was established at a 0.05. All
reported p values are two-tailed.
Results
Patient characteristics
During the study period, 585 consecutive hospitalized
patients with influenza A (H1N1)v virus infection were
included. The demographic and clinical characteristics of
patients are detailed in Tables 1 and 2. Most patients were
under the age of 50 years. Nearly half of the patients had at
least one comorbid condition, with chronic respiratory dis-
ease, immunosuppression and diabetes mellitus being the
most common. Twenty-eight (4.8%) patients were morbidly
obese. Obese and morbidly obese patients had a high preva-
lence of underlying disease (59.3% and 67.9%, respectively).
Ninety-eight patients (16.8%) were pregnant. The median
time from onset of symptoms to hospitalization was 3 days.
The most frequent symptoms and signs on hospital admission
were fever, cough, shortness of breath, muscle aches and
tachycardia. Conversely, altered mental status and hypoten-
sion at presentation were infrequent.
TABLE 1. Demographic character-
istics of patients with pandemic
(H1N1) 2009
All patients
(n = 585)
Patients without
severe disease
(n = 510)
Patients with
severe disease
(n = 75) p
Demographic data
Age, median (range), years 39 (16–87) 38 (16–87) 39 (17–80) 0.26
Age groups, % 96
16–49 years 424 (72.5) 370 (72.5) 54 (72)
50–64 years 111 (19) 96 (18.8) 15 (20)
‡65 years 50 (8.5) 44 (8.6) 6 (8)
Male sex 300 (51.3) 260 (51) 40 (53.3) 0.70
Pregnancy 98 (16.8) 96 (18.8) 2 (2.7) <0.001
Current smoker 184 (31.7) 152 (30.1) 32 (42.7) 0.02
Alcohol abuse 33 (5.7) 24 (4.8) 9 (12) 0.01
Influenza vaccine (season) 62 (12.5) 54 (12.4) 8 (13.8) 0.75
Pneumococcal vaccine, 5 years 23 (4.7) 21 (4.8) 2 (3.5) 0.65
Comorbid conditions
Any one condition 318 (54.4) 262 (51.4) 56 (74.1) <0.001
Chronic pulmonary disease 169 (28.9) 135 (26.5) 34 (45.3) 0.001
Asthma 104 (17.8) 90 (17.6) 14 (18.7) 0.82
COPD 49 (8.4) 34 (6.7) 15 (20) <0.001
OSAS 17 (2.9) 11 (2.2) 6 (8) 0.005
Chronic heart disease 40 (6.8) 30 (5.9) 10 (13.3) 0.01
Chronic renal failure 25 (4.3) 19 (3.7) 6 (8) 0.11
Chronic liver failure 29 (5) 24 (4.7) 5 (6.7) 0.40
Diabetes mellitus 59 (10.1) 49 (9.8) 10 (13.3) 0.31
Immunosuppressed 81 (13.8) 71 (13.9) 10 (13.3) 0.89
HIV/AIDS 26 (4.4) 23 (4.5) 3 (4) 1
Transplant recipients 22 (3.8) 21 (4.1) 1 (1.3) 0.34
Cancer 41 (7) 36 (7.1) 5 (6.7) 0.90
Obesity (BMI ‡ 30–39.9)a 59 (23.2) 50 (21.9) 9 (36) 0.114
Morbid obesity (BMI ‡ 40
and subjective assessment)
28 (4.8) 17 (3.3) 11 (14.7) <0.001
BMI, body-mass index; COPD, chronic obstructive pulmonary disease; HIV/AIDS, human immunodeficiency virus/
acquired immunodeficiency syndrome; OSAS, obstructive sleep apnoea syndrome.
Values given are n (%) unless otherwise stated.
aTwo hundred and fifty-three patients with height and weight available.
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Diagnostic findings
The laboratory and radiographic findings are shown in
Table 3. On admission, most patients had lymphopenia and
elevated C-reactive protein and nearly half had elevated lac-
tate dehydrogenase. Findings consistent with pneumonia on
chest radiography were found in 234 (43.2%) patients. Forty-
five (7.6%) patients had bacterial co-infection. Overall, Strep-
tococcus pneumoniae (28 cases) was the most frequent causa-
tive bacteria followed by methicillin-susceptible Staphylococcus
aureus (four cases), Pseudomonas aeruginosa (four cases)
and Haemophilus influenzae (three cases). Other organisms
isolated were Haemophilus parainfluenzae, Moraxella catharralis,
Streptococcus pyogenes, Escherichia coli, Acinetobacter baumannii
and Streptococcus sanguis.
Treatment and clinical outcomes
The treatment and clinical outcomes are summarized in
Table 4. Oseltamivir was administered to 93.3% of patients.
The treatment was initiated at a median of 3 days after onset
of symptoms. Oseltamivir was given at a dose of 75 mg
twice daily in all but 33 patients, who received 150 mg twice
daily. Antibacterial therapy was administered in 416 (71.7%)
patients. The most commonly used antibiotics were levoflox-
acin (237 cases), ceftriaxone (97 cases) and amoxicillin/clavul-
anate (86 cases).
In-hospital complications developed in 88 (15%) patients.
Severe disease occurred in 75 (12.8%), of whom 71 required
admission to ICU and 13 died. Among the 71 patients
requiring ICU admission, 53 had pneumonia and 52 under-
went mechanical ventilation. Fifty-two (73.2%) of the 71 ICU
patients had chronic comorbid conditions, mainly chronic
pulmonary disease (33 patients), chronic heart disease (ten
patients), diabetes mellitus (ten patients) and immunosup-
pression (seven patients). Only two of 98 pregnant women
required ICU admission. Other in-hospital complications
included viral hepatitis (two cases), catheter-related throm-
bosis of the internal jugular vein (two cases), preterm deliv-
ery (two cases), meningitis/encephalitis (one case), acute
renal failure requiring haemodialysis (one case), diabetic ke-
toacidosis (one case), and oseltamivir-related visual distur-
bances (one case).
The in-hospital mortality was 2.2% (13 of 585 patients)
and the median time from hospital admission to death was
9 days (range, 1–33). Among the 13 patients who died, nine
were under 50 years of age, eight were women, 12 had co-
morbid conditions, two were morbidly obese, 11 had mul-
tilobar pneumonia, and five had bacterial co-infection
(Table 5). Causes of death were respiratory failure/acute
respiratory distress syndrome (three of 13 patients), shock/
multi-organ failure (four patients), decompensated comorbid
condition (four patients) and nosocomial infection (four
patients).
Factors associated with severe disease
Patients with severe disease were more frequently current
smokers and heavy alcohol drinkers and had more comor-
bidities and morbid obesity than patients without severe
disease. Among comorbid conditions, chronic obstructive
TABLE 2. Clinical characteristics of
patients with pandemic (H1N1)
2009
All patients
(n = 585)
Patients without
severe disease
(n = 510)
Patients with
severe disease
(n = 75) p
Clinical features
Reported symptoms
Time from symptoms onset to
hospitalization median (range), days
3 (0–21) 3 (0–21) 3 (1–10) 0.11
Cough, % 525 (89.9) 461 (90.6) 64 (85.3) 0.16
Shortness of breath 274 (46.8) 218 (42.7) 56 (74.7) <0.001
Muscle aches 339 (58.1) 305 (60) 34 (45.3) 0.01
Sore throat 163 (27.9) 147 (28.8) 16 (21.3) 0.17
Headache 187 (32) 174 (34.2) 13 (17.3) 0.003
Rhinorrhoea 119 (20.3) 111 (21.8) 8 (10.7) 0.02
Diarrhoea 61 (10.4) 51 (10) 10 (13.3) 0.37
Vomiting 80 (13.7) 71 (13.9) 9 (12) 0.65
Pleuritic chest pain 97 (16.6) 86 (16.9) 11 (14.7) 0.63
Physical findings
Temperature at admission, median (range), C 38 (35–41) 38 (35–40) 38 (35–41) 0.77
Fever (‡38.0C) 306 (54.6) 270 (55) 36 (52.2) 0.66
Systolic blood pressure median (range), mmHg 120 (65–280) 120 (70–220) 120 (65–280) 0.51
Hypotension (SBP £90 mmHg) 16 (2.9) 10 (2.1) 6 (8.7) 0.002
Cardiac frequency median (range), beats/min 97 (46–160) 96 (46–160) 109 (71–160) <0.001
Tachycardia (‡90 beats/min) 337 (65.9) 280 (63.2) 57 (83.8) 0.001
Respiratory frequency median (range), breaths/min 20 (8–50) 19 (8–45) 28 (10–50) <0.001
Tachypnoea (‡24 breaths/min) 149 (40.1) 112 (34.6) 37 (77.1) <0.001
Impaired consciousness 15 (2.6) 4 (0.8) 11 (14.7) <0.001
Wheezing 169 (29.4) 139 (27.7) 30 (41.1) 0.01
Values given are n (%) unless otherwise stated.
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pulmonary disease, obstructive sleep apnoea syndrome and
chronic heart disease were more frequent in patients with
severe pandemic A(H1N1) 2009. No differences were
found in pneumococcal vaccination and seasonal influenza
vaccination rates between groups. No patient was vacci-
nated against pandemic influenza A(H1N1)v virus. As
regards clinical features, shortness of breath, hypotension,
impaired consciousness and tachypnoea were also more
common in patients with severe disease. Moreover, these
patients were more likely to present lymphopenia and
thrombocytopenia and they had significantly higher liver
enzyme, lactate dehydrogenase and C-reactive protein
levels. Among radiological and microbiological findings, they
also had a higher prevalence of pneumonia and bacterial
co-infection.
The mean time from onset of symptoms to oseltamivir
administration was significantly longer in patients with severe
disease (95% CI of mean difference 0.3–2.1 days). Mean
length of hospital stay was also significantly longer in these
patients (95% CI of mean difference 7.7–15 days).
TABLE 3. Diagnostic findings of patients with pandemic (H1N1) 2009
All patients
(n = 585)
Patients without
severe disease
(n = 510)
Patients with
severe disease
(n = 75) p
Laboratory findings
Leucocyte count median (range), per mm3 7230 (240–41400) 7100 (300–41400) 8870 (240–23380) 0.003
Leukopenia (<4000 per mm3), % 84 (14.5) 74 (14.7) 10 (13.3) 0.76
Leukocytosis (‡12000 per mm3) 76 (13.1) 55 (10.9) 21 (28) <0.001
Lymphopenia (lymphocytes <1500 cells per mm3) 468 (81.5) 401 (80.4) 67 (89.3) 0.06
Hematocrit median (range), % 40.1 (17–57) 40 (17–57) 41 (27–56) 0.15
Anaemia (Hcto <36%) 146 (25.3) 130 (25.9) 16 (21.3) 0.39
Platelet count, median (range), per mm3 187 000 (7000–467 000) 188 000 (7000–467 000) 167 500 (67 000–381 000) 0.27
Thrombocytopenia (<150,000 per mm3) 153 (26.7) 127 (25.5) 26 (35.1) 0.08
Alanine aminotransferase, median (range), IU/L 28 (6–840) 27 (6–840) 53 (11–350) <0.001
Elevated alanine aminotransferase (>40 IU/L) 119 (31.7) 89 (27.5) 30 (58.8) <0.001
Aspartate aminotransferase median (range), IU/L 29 (9–429) 27.5 (9–400) 45.2 (16.8–429) <0.001
Elevated aspartate aminotransferase (>40 IU/L) 105 (28.9) 78 (24.8) 27 (55.1) <0.001
Creatine phosphokinase, median (range), IU/L 94 (9–6096) 87 (9–6096) 110 (18–640) 0.15
Elevated creatine kinase (>240 IU/L) 34 (20.1) 26 (18.2) 8 (30.8) 0.14
Lactate dehydrogenase, median (range), IU/L 335 (31–3545) 325 (31–1519) 427 (32–3545) 0.004
Elevated lactate dehydrogenase (>350 IU/L) 131 (46.3) 105 (42.9) 26 (68.4) 0.003
C-reactive protein, median (range), mg/L 43.7 (1–506) 40 (1–398) 75 (4.1–506) <0.001
Elevated C-reactive protein (>20 mg/L) 264 (75.9) 222 (73.8) 42 (89.4) 0.02
PaO2/FiO2, median (range) 295.6 (47–519) 304.8 (83.5–519) 233.3 (47–342) <0.001
Respiratory failure (PaO2/FiO2 < 300 or oxygen saturation <90%) 172 (33.2) 112 (25.2) 60 (82.2) <0.001
Concomitant/secondary bacterial co-infectiona 45 (7.6) 31 (6.3) 14 (18.9) <0.001
Radiographic findings
Infiltrates on chest radiography 234 (43.2) 178 (38) 56 (75.7) <0.001
Multilobar infiltratesb 135 (57.7) 89 (50) 46 (82.1) <0.001
PaO2/FiO2, partial pressure arterial oxygen/fraction of inspired oxygen.
Values given are n (%) unless otherwise stated.
aSix patients had more than one microorganism.
bPercentages from patients with pneumonia.
TABLE 4. Treatment and clinical
outcomes of patients with pan-
demic (H1N1) 2009
All patients
(n = 585)
Patients without
severe disease
(n = 510)
Patients with
severe disease
(n = 75) p
Treatment
Antiviral treatment, % 545 (93.3) 473 (92.9) 72 (96) 0.32
Time from symptoms onset to
antiviral therapy, median (range), days
3 (1–21) 3 (1–21) 4 (1–21) 0.004
Early treatment (£72 h after symptoms onset) 297 (57) 272 (59.6) 25 (38.5) 0.001
Antibacterial treatment 416 (71.7) 342 (67.6) 74 (100) <0.001
Corticosteroids 160 (28) 118 (23.6) 42 (58.3) <0.001
Clinical outcomes
Length of hospital stay, median (range), days 5 (1–98) 5 (1–28) 11 (1–98) <0.001
In-hospital complications
Shock 26 (4.5) 1 (0.2) 25 (33.8) <0.001
Nosocomial infections 16 (2.7) 4 (0.8) 12 (16) <0.001
Heart complications 12 (2.1) 2 (0.4) 10 (13.3) <0.001
ICU admission 71 (12.1) – –
Mechanical ventilation 52 (8.9) – –
ARDS 23 (3.9) – –
In-hospital mortality 13 (2.2) – –
ARDS, acute respiratory distress syndrome; ICU, intensive-care unit.
Values given are n (%) unless otherwise stated.
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The results of multivariate logistic regression analysis for
factors potentially associated with severe disease are shown
in Table 6. Independent factors associated with severe dis-
ease were age <50 years (OR, 2.39; 95% CI, 1.05–5.47),
comorbid conditions (OR, 2.93; 95% CI, 1.41–6.09), morbid
obesity (OR, 6.74; 95% CI, 2.25–20.19), concomitant and/or
secondary bacterial co-infection (OR, 2.78; 95% CI, 1.11–7)
and early oseltamivir therapy (£72 h) (OR, 0.32; 95% CI
0.16–0.63).
Discussion
In this prospective, multicentre study of a large number of
adults hospitalized for pandemic influenza (H1N1)v virus
infection in Spain, independent factors associated with severe
disease were younger age, chronic comorbid conditions,
morbid obesity and bacterial co-infection. Conversely, early
oseltamivir therapy was a protective factor.
Characteristics and clinical outcomes of our study patients
were similar to those described elsewhere [5,11,21–23].
Although our mortality rate was lower than that reported in
the earliest studies of hospitalized patients [5,14,23], our
findings concur with those of more recent reports [24–26].
Previous studies found that current [5,11,22,27] and past
pandemics [28] affected mainly younger patients. Similarly,
adult patients younger than 50 years had a higher risk of
death during the 1918 Spanish influenza pandemic [28] and
during the recent H5N1 avian influenza [29]. Nevertheless,
studies involving patients with pandemic (H1N1) 2009 found
that although older patients had the lowest estimated inci-
dence rate, they also had the highest case fatality rate
[9,15,23]. In the present study, we found that among hospi-
talized adults, younger patients had a higher risk of severe
disease, in agreement with the finding of earlier studies of
critically ill patients [11,21]. Only 8.5% patients of our cohort
were over 65 years old. The low prevalence of older
patients in pandemic (H1N1) 2009 has been attributed to
residual immunity against influenza A (H1N1) strains in peo-
ple born before 1950 [30,31].
Other independent factors associated with severe disease
identified in our study, such as chronic morbid conditions
and morbid obesity, have previously been associated with
ICU admission or mortality [5,11,15,16]. Regarding comor-
bidities, chronic obstructive pulmonary disease, obstructive
sleep apnoea syndrome and chronic cardiac disease were
more common in patients with severe disease than in the
others. In our study, although asthma was the most frequent
underlying condition, no difference was found in its preva-
lence between patients with and without severe disease.
Conversely, O’Riordan et al. [32] and Libster et al. [33]
reported that asthma was a significant risk factor for ICU
admission and mortality among children admitted to hospital.
Similarly, during previous influenza pandemics and interpan-
demic periods, patients with impaired cardiopulmonary func-
tion have presented a higher risk of complications [34].
We found that patients with morbid obesity had a higher
risk of severe disease. Morbidly obese patients also had fre-
quent comorbidities, especially obstructive sleep apnoea syn-
drome and diabetes mellitus. Interestingly, a recent study
demonstrated that obese mice infected with influenza virus
have diminished cell cytotoxicity, delayed pro-inflammatory
cytokine expression, and higher mortality than lean mice
controls [35]. Future investigations are needed to clarify the
pathophysiology underlying the association of morbid obesity
and severe influenza infection.
There is evidence that influenza virus alters the host
inflammatory response and predisposes to adherence, inva-
sion, and induction of disease by bacterial microorganisms. It
has long been recognized that bacterial co-infection compli-
cates the course of illness for many patients with influenza
infection. In fact, during the influenza pandemics of the twen-
tieth century, secondary bacterial pneumonia was an impor-
tant cause of illness and death and S. pneumoniae was
reported to be the most common aetiology. In the present
study, S. pneumoniae was by far the most frequently isolated
microorganism. Although prevalence of bacterial co-infection
in our study was relatively low, it was an independent factor
for severe disease. The synergistic interaction between bac-
teria and influenza virus has been shown to contribute to
the severity of the resulting infection in animal models [36].
Moreover, Palacios et al. [37] recently reported that identifi-
cation of S. pneumoniae in nasopharyngeal swab samples from
patients with pandemic (H1N1) 2009 was also a factor
related to severe disease. Other investigators have found a
high frequency of bacterial co-infection in lung tissue speci-
mens from fatal cases of influenza (H1N1)v virus infection
TABLE 6. Factors associated with severe pandemic (H1N1)
2009: multivariate analysis
Odds
ratio
95% confidence
interval p
Age (16–49 years) 2.39 1.05–5.47 0.03
Male sex 0.74 0.38–1.45 0.39
Current smoker 1.08 0.53–2.22 0.82
Alcohol abuse 2.20 0.64–7.52 0.20
Comorbid condition 2.93 1.41–6.09 0.004
Morbidly obese 6.74 2.25–20.19 0.001
Influenza vaccine (season) 0.94 0.36–2.44 0.90
Early antiviral treatment (£72 h) 0.32 0.16–0.63 0.001
Concomitant and/or secondary
bacterial co-infection
2.78 1.11–7.00 0.02
744 Clinical Microbiology and Infection, Volume 17 Number 5, May 2011 CMI
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 738–746
[38,39] and the 1918–1919 influenza pandemic [40]. In this
regard, pneumococcal vaccination has been recommended as
a key element in influenza preparedness plans [41].
No randomized controlled trials of neuraminidase inhibi-
tors in patients admitted to hospital with influenza virus
infection have been carried out to date. Therefore, deter-
mining the effect of antiviral treatment on complications in
hospitalized patients during the current pandemic is a criti-
cal issue. In previous studies [13,23], early administration of
antiviral treatment was associated with favourable outcome
and with lower development of respiratory failure in
patients with influenza A (H1N1)v 2009 virus infection. We
found that patients who received early oseltamivir treat-
ment tended to have more comorbidities, but had less evi-
dence of pneumonia and bacterial co-infection (data not
shown). These patients also had a significantly lower risk of
severe disease. Although no solid conclusions can be estab-
lished based on observational studies alone, these findings
suggest that giving early antiviral treatment to hospitalized
patients with pandemic (H1N1) 2009 might prevent
complications.
The present study was conducted in geographically diverse
settings all across Spain during the first wave of the pan-
demic, before the introduction of the vaccination campaign
against the influenza A(H1N1)v virus. Strengths of the study
are its prospective and multicentre design, the large number
of patients included and the comprehensive clinical data col-
lection. These characteristics improve the external validity of
the results. However, our study has some limitations that
should be acknowledged. First, physicians did not use a uni-
form strategy for determining admission, and so factors
other than disease severity may have contributed to site-of-
care decisions. In this regard, it should be noted that preg-
nant women did not have a higher risk of severe disease in
the present study. It is possible that some pregnant women
were hospitalized in spite of having mild disease and received
early antiviral treatment more frequently. Second, bacterial
co-infection may have been underestimated because microbi-
ological studies were not performed routinely in all patients.
In addition, these tests have some limitations in identifying
the causative organisms of pneumonia. However, it is impor-
tant to note that two or more bacterial microbiological stud-
ies were performed in about 78% of patients with
pneumonia in this study.
In conclusion, although hospitalized adults with pandemic
(H1N1) 2009 suffer from significant morbidity, mortality is
lower than that reported in the earliest studies. Younger
age, comorbidities, morbid obesity and bacterial co-infection
are independent risk factors for severe disease, whereas
early oseltamivir therapy is a protective factor.
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